Overview

This trial is active, not recruiting.

Conditions diffuse large b-cell lymphoma, lymphoma, diffuse large-cell, diffuse large-cell lymphoma, lymphoma
Treatments bendamustine, rituximab
Phase phase 2
Target CD20
Sponsor UNC Lineberger Comprehensive Cancer Center
Collaborator Cephalon
Start date November 2010
End date August 2016
Trial size 37 participants
Trial identifier NCT01234467, 10-1405, LCCC 1011

Summary

The purpose of this research study is to learn about the safety of the treatment with a combination of bendamustine and rituximab and to find out what effects, both good and bad this treatment has on DLBCL. In addition to learning about the combination of bendamustine and rituximab, the researchers are interested in learning about how this cancer treatment affects daily activities. Subjects will be asked to complete a Geriatric Assessment (GA). GAs are designed to gather information on memory, nutritional status, mental health, and level of social support. GAs are also designed to help the health care team understand how well subjects can carry out their day to day activities and to briefly describe what other medical conditions subjects may have. This assessment will help the health care team understand a subject's "functional age" (the age a subject functions at) as compared to a subject's actual age.

The researchers also want to learn how chemotherapy affects the aging process in our bodies. This is done by measuring the amount of p16 in blood. Researchers want to understand if chemotherapy changes the levels of p16 in blood.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
bendamustine TREANDA
Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
rituximab Rituxan
Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles

Primary Outcomes

Measure
Complete response (CR) rate as defined by The International Harmonization Project for Response Criteria
time frame: 2 years

Secondary Outcomes

Measure
Overall response rate (ORR, CR + PR)
time frame: 2 years
Estimate the disease-free survival (DFS), progression-free and overall survival
time frame: 3 years
Evaluate the toxicity and tolerability of bendamustine in combination with rituximab
time frame: 3 years

Eligibility Criteria

Male or female participants at least 65 years old.

Inclusion Criteria: - Patients with previously untreated , histologically confirmed, diffuse large B-cell lymphoma (DLBCL), immunophenotyped for CD20 - Age greater than or equal to 65 years - Stage II-IV - Measurable disease including lesions that can be accurately measured in 2 dimensions by CT and have a greatest transverse diameter of 1cm or greater, and/or by bone marrow histopathology. - ECOG performance status of 0-3 - Deemed poor candidate for CHOP-R due to ejection fraction less than or equal to 45%, ECOG performance status of 2, or in the opinion of the treating physician, patient would not tolerate administration of CHOP-R chemotherapy for other reasons, - Life expectancy of at least 3 months; - Documented negative serologic testing for HIV, Hepatitis B (unless positive due to prior vaccination), and hepatitis C within the year prior to enrollment - Adequate bone marrow function (without transfusion support within one week of screening) function: - Hemoglobin > 8 g/dL - Absolute neutrophil count (ANC) >1000 cells/mm3 - Platelet count > 75,000/mm3 - Adequate hepatic and renal function as demonstrated by: - Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN) - Total serum bilirubin < 2.5 x ULN - Serum creatinine < 1.5 x ULN - If sexually active male of reproductive capability, has agreed to use a medically accepted form of contraception from time of enrollment to completion of all follow-up study visits - Signed an institutional review board (IRB) approved informed consent document Exclusion Criteria: - Central nervous system involvement by lymphoma - History of previous allergic reactions to compounds of similar biological or chemical composition as rituximab or bendamustine - Medical or other condition that would represent an inappropriate risk to the patient or would likely compromise achievement of the primary study objective. - Other active malignancies (except: non-melanoma skin cancer, cervical carcinoma in situ without evidence of disease, prostatic intraepithelial neoplasia without evidence of prostate cancer) - Patients on strong inhibitors of CYP1A2.

Additional Information

Official title A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Principal investigator Steven Park, MD
Description This multicenter Phase II clinical study will investigate the complete response (CR) rate after therapy with bendamustine combined with rituximab in older (≥65 years old) patients with previously untreated stage II-IV DLBCL deemed poor candidates for cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin®), prednisone, rituximab (CHOP-R); n=37. The hypothesis being tested is that this regimen will be safe and effective as frontline therapy in older DLBCL patients deemed poor candidates for CHOP-R. After 3 cycles of therapy, patients with less than a partial response (PR) will come off study, and be managed at the discretion of their treating physician. Patients who achieve a PR after 3 cycles will continue for a total of 8 cycles of therapy, while patients who achieve a CR will continue for a total of 6 cycles of therapy. Secondary objectives include overall response rates (ORR), disease-free, progression-free and overall survival, and an evaluation of the toxicity and tolerability of the regimen. This trial also includes an exploratory analysis designed to evaluate a potential correlation between expression of the senescence marker p16INK4a and the toxicity associated with this regimen. In addition, patients will be asked to participate in a Geriatric Assessment (GA) tool during the trial.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center.